Should You Buy Black Diamond Therapeutics, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Black Diamond Therapeutics, Inc. (BDTX) scores a robust 7.5/10 on our 32-signal Quality of Company framework. At the current market price of $1.97 and a $113M market cap, our analysis maps this fundamental strength against 13 institutional-grade models to determine if a sufficient margin of safety exists.
The short answer: 5 of 7 CirclFi valuation models project upside for Black Diamond Therapeutics, Inc. (BDTX) at $1.97 — the model consensus leans bullish, with a Quality Score of 7.5/10 and Value-Trap risk of 43/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Black Diamond Therapeutics, Inc. (BDTX) in 2026?
What Is the Bull Case vs the Bear Case for Black Diamond Therapeutics, Inc. (BDTX)?
| Bull case — $3.78 target (+91.8%) | Bear case — $0.35 target (-82.0%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, Black Diamond Therapeutics, Inc.'s rating of 7.5/10 signals strong fundamentals — high-quality businesses tend to compound value more reliably. | According to the CirclFi Value Trap algorithm, the stock shows moderate caution signals, meaning investors should verify that apparent undervaluation isn't masking declining business quality. |
| According to the CirclFi Deep Alpha Valuation Engine, 5 of 7 models identify upside from $1.97 to a median fair value of $2.82, indicating the market hasn't fully priced in Black Diamond Therapeutics, Inc.'s earnings power. | According to the CirclFi Deep Alpha Valuation Engine, the Sentiment SOTP model sees the stock as overvalued with a fair value of $0.35 (-82.0%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the RCMH-DCF model targets a fair value of $3.78 (+91.8%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +173.8% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology. |
| Industry tailwind: gene therapy and cell therapy innovation could provide meaningful support for Black Diamond Therapeutics, Inc.'s revenue and margin trajectory in the Biotechnology space. | Industry headwind: manufacturing scale-up challenges represents a meaningful risk for Black Diamond Therapeutics, Inc. and its Biotechnology peers. |
How Does BDTX Compare to Its Biotechnology Peers?
Valuation data pages: JAZZ · SPRO · ARWR · TWST · GYRE · BNTX · NRXS · PVCT · HCWB · EXEL · INCY
Which Other Stocks Score Like BDTX on Quality?
Closest companies to BDTX’s Quality of Company score of 7.5/10, across all industries.
Which Biotechnology Screens Does BDTX Appear In?
So Is Black Diamond Therapeutics, Inc. (BDTX) Worth Buying in 2026?
Black Diamond Therapeutics, Inc. leans positive in our analysis — 5/7 models bullish, median fair value of $2.82 vs. $1.97, QOC 7.5/10. The case is constructive but not overwhelming, and the 2 dissenting models shouldn't be dismissed. Position sizing should reflect this moderate conviction level.
These are quantitative model outputs, not investment recommendations. Black Diamond Therapeutics, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About BDTX Stock?
Should I buy BDTX stock right now?
Based on CirclFi's multi-model analysis, 5 of 7 models see upside for BDTX at $1.97. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 7.5/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Black Diamond Therapeutics, Inc.?
Key risks include: an elevated Value Trap score of 43/100, suggesting apparent undervaluation may mask deteriorating fundamentals; limited model coverage (7/13 active), reducing analytical confidence; wide model disagreement (965% spread), signaling high uncertainty; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.
How does BDTX compare to its competitors?
Among Biotechnology peers, BDTX holds a Quality Score of 7.5/10. Comparable companies include JAZZ (QOC 7.6), SPRO (QOC 7.4), ARWR (QOC 7.6). The relative ranking helps investors identify whether BDTX offers better fundamental quality than alternatives in the same sector.
Is BDTX a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. BDTX's Quality Score of 7.5/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy BDTX at?
CirclFi does not provide target buy prices or price alerts. However, our 7 active models produce fair value estimates ranging from $0.35 to $3.78. At $1.97, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for BDTX.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad